Chemomab Therapeutics Ltd.

CMMB

US16385C1045

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2025-01-17 pm EST			5-day change	1st Jan Change
2.140 ^USD	+9.74%		+8.08%	+18.23%

Nov. 19	Chemomab Therapeutics Ltd. Announces Data from its Phase 2 SPRING Trial in Patients with Primary Sclerosing Cholangitis	CI
Nov. 15	Oppenheimer Adjusts Chemomab Therapeutics Price Target to $11 From $13, Maintains Outperform Rating	MT

Chemomab Therapeutics to Raise $10 Million From Private Placement; Shares Fall

July 25, 2024 at 02:18 pm EDT

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd. Announces Data from its Phase 2 SPRING Trial in Patients with Primary Sclerosing Cholangitis	Nov. 19	CI
Oppenheimer Adjusts Chemomab Therapeutics Price Target to $11 From $13, Maintains Outperform Rating	Nov. 15	MT
Chemomab Therapeutics Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	24-08-21	CI
Chemomab Therapeutics Ltd. announced that it has received $9.999607 million in funding	24-07-29	CI
Chemomab Therapeutics to Raise $10 Million From Private Placement; Shares Fall	24-07-25	MT
Chemomab Therapeutics Announces Positive Phase 2 Trial Results: Cm-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis	24-07-25	CI
Chemomab Therapeutics Ltd. - Special Call	24-07-25
Chemomab Therapeutics Ltd. announced that it expects to receive $9.000001 million in funding	24-07-24	CI
Chemomab Therapeutics Ltd. Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis	24-06-18	CI
Oppenheimer Upgrades Chemomab Therapeutics to Outperform	24-05-06	MT
Chemomab Therapeutics Ltd. - Special Call	24-04-10
Chemomab Therapeutics Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	24-03-07	CI
Chemomab Therapeutics Ltd. Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis	24-01-30	CI
Chemomab Therapeutics Ltd. Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024	24-01-03	CI
ADRs Advance, YPF S.A. Climbs 39.9%	23-11-20	DJ
ADRs Advance, Missfresh Ltd. Climbs 23.3%	23-11-17	DJ
ADRs End Lower; VNET Group Declines 26%	23-11-16	DJ
ADRs Slump; FLJ Group Ltd. Declines 13.7%	23-11-15	DJ
Top Midday Gainers	23-11-15	MT
Chemomab Therapeutics Ltd. Announces U.S. Food and Drug Administration Grants CM-101 Fast Track Designation for Treatment in Adult Patients of Primary Sclerosing Cholangitis	23-11-15	CI
Chemomab Therapeutics Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-11-09	CI
Roth MKM Starts Chemomab Therapeutics at Buy, $7 Price Target	23-10-06	MT
Chemomab Therapeutics to Present Its CM-101 Clinical Program in Primary Sclerosing Cholangitis At 2023 Roth MKM Healthcare Opportunities Conference	23-09-28	CI
Chemomab Therapeutics Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Chemomab Therapeutics Announces Publication in JCI Insight Demonstrating Key Role of CCL24 in Primary Sclerosing Cholangitis	23-06-28	CI

Chart Chemomab Therapeutics Ltd.

Duration

Period

CMMB: Dynamic Chart

Chemomab Therapeutics Ltd, formerly known as Anchiano Therapeutics Ltd, is a Israel-based biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.

Employees

Sector

Biotechnology & Medical Research

Calendar

2025-03-05 - Q4 2024 Earnings Release (Projected)

More about the company